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however. Hamad General, in HMC, was the major consumer of cardiovascular 
drugs. The class with the most significant (and highest utilization) in HG was the 
statins (p-value 0.04). Among statins, atorvastatin was increasingly the most 
used. An identical pattern of expenditures to that of utilization was observed for 
all drug classes. Apart from all combination therapies, the combining of 
angiotensin-receptor-blockers with diuretics was the only one increasing in use. 
CONCLUSIONS: Utilization and expenditures of cardiovascular drugs have 
steadily increased over the past 5 years in Qatar. Reasons for increasing trends in 
utilization can include fast growing population, in addition to newer clinical trial 
evidences as well as updated guidelines.  
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OBJECTIVES: Drugs of first choice in the treatment of hypertension are: β-
blockers, tiazide diuretics, ACE inhibitors, angiotensin receptor inhibitors and Ca 
channel blockers. The aim of this study was to analyze the consumption of 
antihypertensive drugs in Serbia in the period from 2006 to 2010 year. METHODS: 
The data about the use of drugs were taken from the Agency for Drugs and 
Medical Devices of the Serbia. RESULTS: The use of diuretics during the observed 
period in Serbia is quite small and it ranged from 5 to 6% of the total 
consumption of all drugs from the C group. Consumption of β-blockers was 
around 12% during all 5 years. Consumption of calcium channel blockers was 
less than 14% of the total consumption of all drugs from group C in the first 3 
years of the observed period. However, consumption of such drugs in the last 2 
years growing over 17% of the total consumption of all drugs from the C group. 
Total consumption of drugs acting on the renin-angiotensin system (C09) in 
Serbia in opserved period was over 40 % of the total consumption of all drugs 
from the C group. The highest percentage in this group belonged to the ACE 
inhibitors. Consumption of angiotensin receptor inhibitors is small and it is only 
a few percent of the total consumption of all drugs from C09 group. However, 
consumption of drugs in this subgroup recorded steady growth in recent years. 
CONCLUSIONS: In Serbia in the observed period, ACE inhibitors are the most 
frequently used drugs within the group of drugs which is used for treatment of 
hypertension. This research was supported by Provincial Secretariat for Science 
and Technological Development, Autonomous Province of Vojvodina project No 
114-451-2458/2011 and by Ministry of Science, Republic of Serbia, project no 
41012.  
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OBJECTIVES: Hyperlipidemia is a major risk factor for cardiovascular diseases, 
and treatment and control of hyperlipidemia reduces risk. The objective of this 
study was to examine trends in the prevalence of hyperlipidemia, awareness, 
treatment, and control among United States adults. METHODS: We used data of 
13,112 United States adults (age ≥20 years) who participated in the National 
Health and Nutrition Examination Survey (NHANES) from 2001 to 2010 (this is a 
cross-sectional health examination survey of the US population) and who had a 
diagnosis for hyperlipidemia or reported using cholesterol-lowering medications 
and who participated in the National Health and Nutrition and had a total 
cholesterol determination. RESULTS: The prevalence of hyperlipidemia ranged 
from 55.58% to 53.83% and changed little over the study period. For all adults, the 
age-adjusted mean total cholesterol concentration decreased from 225.75±2.87 to 
215.55±3.39 (p<0.01). Significant decreases were observed among African 
American population. Among participants who had a total cholesterol 
concentration > 200 mg/dL or who reported using cholesterol-lowering 
medications, 28.9% were aware that they had hyperlipidemia, 26.2% were on 
treatment, and 12.0 had a total cholesterol concentration < 200 mg/dL after age 
adjustment. Lifestyle proved to play a major role is control of hyperlipidemia. 
The smokers were 3-4% (p<0.001) less in the control group as compared to non-
smokers. The people who engaged in vigorous intensity activity were 2-3% 
(p<0.001) more in the control group than the ones who engaged in moderate 
intensity activity. Insurance played an important role in treatment. Percent of 
population with insurance receiving treatment was about 50% (p<0.001) more 
than the percent of population without insurance. CONCLUSIONS: Although the 
increases in awareness and treatment of hyperlipidemia are encouraging, 
control remains poor. The lower percentage of controlled blood cholesterol 
stresses the need for better prevention and treatment programs for 
hyperlipidemia.  
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HIGH-RISK VASCULAR DISEASE IN JAPAN: EVIDENCE ON INCIDENCE, PATIENT 
CHARACTERISTICS, AND TREATMENT RATES FROM A LARGE JAPANESE 
CLAIMS DATABASE  
Davis KL1, Meyers J1, Zhao Z2, McCollam P3, Murakami M4 
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Eli Lilly and Company, Indianapolis, IN, 
USA, 3Eli Lilly & Company, Indianapolis, IN, USA, 4Lilly Research Laboratories, Japan, Kobe, 
Japan  
OBJECTIVES: To document incidence, patient characteristics, and treatments of 
high-risk vascular disease (HRVD, defined as history of acute coronary syndrome 
[hACS], cerebrovascular disease [CVD], peripheral artery disease [PAD], or 
coronary artery disease w/diabetes [CADD]) in an employed Japanese population. 
METHODS: A retrospective analysis was conducted using the Japan Medical Data 
Center (JMDC) database, which comprises multiple employer-sourced insurance 
societies in Japan, with inpatient, outpatient, and pharmacy claims of ~800,000 
lives from 2006–2011. HRVD incidence was estimated based on diagnoses for 
CVD, PAD, CADD, and hACS (defined as another ACS claim >30–≤365 days after 
an ACS-related hospitalization) occurring between January 1, 2008 to December 
31, 2009. Population denominators for this period were provided by JMDC. A 
subcohort with insurance coverage for ≥12 months before and ≥24 months after 
first/index HRVD claim during January 1, 2008 to December 31, 2009 were 
analyzed on demographics, comorbidities, and treatments. RESULTS: HRVD 
incidence was 2,238 per 100,000 population. By subtype (non-mutually exclusive), 
incidence was 73 hACS, 1,289 CVD, 897 PAD, and 591 CADD per 100,000; 22% had 
≥2 HRVD subtypes. hACS and CADD incidence per 100,000 was markedly higher 
in males (111 and 730, respectively) versus females (35 and 409). In total, 10,400 
patients met the inclusion criteria for analyses of patient characteristics, 
comorbidities, treatments. Mean [SD] age at index was 52.8 [10.9] years and 57% 
were male. Comorbid hypertension and dyslipidemia were common (24% and 
17%, respectively). Pre-index use of antihypertensives and lipid-altering drugs 
was 22% and 15%, respectively. During 24 months post-index, use of these agents 
increased to 53% and 42%. Post-index use of antiplatelets (including prescription 
aspirin), anticoagulants, and NSAIDs was 30%, 15%, and 66%, respectively, with 
substantially higher use in hACS patients. CONCLUSIONS: HRVD was not rare in 
the employed Japanese population analyzed, and a high proportion of cases 
involved multiple HRVDs. Pharmacotherapy after HRVD diagnosis appeared 
suboptimal, particularly for non-hACS patients.  
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OBJECTIVES: Previous research suggests elderly patients with type-2 diabetes 
mellitus (T2DM) are likely discharged without anti-hyperglycemic medication 
after an admission for myocardial infarction (MI). Our study aimed to evaluate 
anti-hyperglycemic medication use post-MI in a commercially insured 
population. METHODS: We assembled a nation-wide population-based cohort of 
patients with T2DM continuously enrolled by a private insurer between January 
2007 and December 2009. T2DM was defined based on diagnosis codes (Chronic 
Condition Data Warehouse definition) and pharmacy claims for an anti-
hyperglycemic drug. We identified patients who experienced MI (ICD-9 code 
410.xx) during our study period and evaluated anti-hyperglycemic treatment 
before and after the cardiac event. We described medication utilization and 
investigated changes in medication use from pre- to post-MI. Logistic regression 
and resulting odds ratios (OR) with associated 95% confidence intervals (CI) were 
used to evaluate factors predicting treatment post-MI. RESULTS: We identified 
25,136 diabetic patients that experienced MI. Prior to MI, over 30% of the patients 
had a prescription for an anti-hyperglycemic drug, with approximately 12% 
receiving multiple drug regimens. The majority of the patients were treated with 
metformin (42%), followed by a sulfonylurea agent. Post-MI, 34% were treated; of 
the 75% with a prescription within 30 days, 35% received metformin. The median 
time from discharge until the first prescription fill was 25 days (interquartile 
range=62). About 29% of those treated pre-MI, did not receive medication post-
MI; about 1 in 8 patients initiated anti-hyperglycemic medication within 30 days 
post-MI. Demographic characteristics and pre-MI treatment predicted treatment 
after MI. Older patients were less likely to fill a prescription post-MI (adjusted 
OR=0.974; 95% CI: 0.972-0.977). CONCLUSIONS: Many T2DM patients 
experiencing an MI are not discharged on previously prescribed anti-
hyperglycemic medications. Assessment of short and long-term outcomes in 
patients not receiving anti-hyperglycemic medications post-MI, particularly in 
the elderly, warrants further investigation.  
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OBJECTIVES: To examine geographic variation associated with atrial fibrillation 
(AF) prevalence in the U.S. veteran population as well as the distribution of AF, 
stratified by age. METHODS: This study analyzed a patient sample in the 
Veterans Health Administration (VHA) Medical SAS datasets (October 1, 2005 - 
May 31, 2012). All patients diagnosed with AF in 2011 were identified using 
International Classification of Disease 9th Revision Clinical Modification (ICD-9-
CM) diagnosis code 427.31. AF prevalence, stratified by U.S. state and age group, 
was determined. Descriptive statistical analyses were performed using SAS v9.3 
software. RESULTS: A total of 1,255,349 veteran patients were diagnosed with AF 
in 2011. Prevalence results showed an increase as patient age rose (age 18-25: 
0.02%, 16-34: 0.05%, 35-54: 0.39%, 55-64: 2.0%, 65+: 6.06%). Prevalence also varied 
by state. AF was most prevalent in Vermont (5.05%), Connecticut (4.75%), 
Massachusetts (4.64%) and Utah (4.62%). AF had low prevalence in Hawaii 
(1.99%), Colorado (1.96%), Guam (1.69%) and Washington D.C. (1.62%). All states 
throughout the United States showed disease prevalence above 1.5%, but none 
had a rate greater than 5.5%. Only Vermont was observed with prevalence 
slightly greater than 5.0%. CONCLUSIONS: U.S. veterans living in Utah and in the 
Northeastern U.S. region (including Vermont, Massachusetts, and Connecticut) 
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had high regional prevalence of AF in 2011. Geographic variation in high risk 
areas can help identify important geographically connected prognostic factors, 
aid in targeted intervention strategies, and generate hypotheses regarding 
underlying causes of AF in the United States and associated territories.  
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OBJECTIVES: To estimate the disease burden of atrial fibrillation and to describe 
its impact on Colombian population health METHODS: We calculated Disability 
Adjusted Life Year (DALYs) for atrial fibrillation, by adding years of life lost due 
to premature mortality (YLL) plus years lived with disability (YLD). For 
calculating YLL it were consulted both death registration and abridged-life tables 
at national statistic agency DANE for 2000-2009. For calculating YLD it were 
consulted individual records of service providers for 2009-2010. It were also 
consulted the map of weighted disability from the Global Burden of Disease 
study. For data processing we used a template developed in Microsoft Excel® 
according to the method described by WHO in October 2001 and taking into 
account the parameters and formulas that have been described by Murray and 
Lopez (1996) and Mathers et al (2001). RESULTS: In 2000, 2004 and 2009 it was lost 
due to atrial fibrillation 12,138; 13,188 and 15,327 DALYs in the Colombian 
population with a ratio of 0.30, 0.31 and 0.34 DALY per thousand people 
respectively. The relative weight of DALYs was given by the disability component 
(91.46%). Men accounted for an average of 58% of estimated DALYs; and the most 
affected age was that of 70-79 years old CONCLUSIONS: The estimated DALYs 
show that atrial fibrillation is a disease highly disabling in the Colombian 
population during the study period, given the predominance of the component 
of years lived with disability (YLD).  
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OBJECTIVES: Most of the studies of time distribution of stroke onset in the 
Chinese population have a limited number of cases, and national-level data 
analysis is rare. In this study, circadian rhythm of stroke onset in the Chinese 
patients was observed on the basis of the China National Stroke Registry (CNSR) 
data. METHODS: Continuous prospective registration of new-onset acute 
cerebrovascular events within 14 days was conducted based on nationwide 
multi-center, continuity, prospective stroke registry data, and 1-year follow-up 
was performed to analyze the differences in time pattern and prognosis of the 
onset of strokes of different etiological subtypes and clinical sub-types. 
RESULTS: A total of 9588 people entered the statistical description after cases 
with absence of time of onset and wake-up stroke were excluded from all of the 
stroke cases (including IS, ICH, SAH, TIA). The period from 7:00 to 12:00 appeared 
to be a significant peak for stroke onset. According to different stroke sub-types, 
onset peak in the morning was more prominent in 5796 cases of IS and 399 cases 
of TIA; 2,666 cases of ICH and 399 cases of SAH presented two onset peaks from 
7:00 to 12:00 and from 17:00 to 19:00. The cases showed the same trend 
irrespective of initial onset or recurrence and with or without hypertension. 
Through logistic regression model analysis, gender, age, history of Arial 
Fibrillation, smoking history and other factors were related to the time of stroke 
onset to a certain extent. CONCLUSIONS: The time of stroke onset in Chinese 
patients is generally in the morning. The trend of IS onset is particularly evident. 
Therefore, paying more attention to morning care and blood pressure control 
during morning will be important.  
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OBJECTIVES: Heart Failure (HF) is a leading cause of morbidity and mortality in 
the US, and hospitalization for HF appears to be steadily increasing. We sought 
to identify HF patients and understand the patterns of care for HF in a real-world 
setting through analysis of a retrospective observational database. METHODS: 
The study population consisted of patients in the Medicare 5% database with a 
primary inpatient diagnosis of HF (ICD-9-CM 428.0, 428.9, 428.20-23, 428.30–33, 
428.40–43) during CY2005–2008. Patients were followed for up to 33 months (6 
months baseline, 3 month index, 24 months follow-up. To exclude prevalent 
cases, patients were required to have no diagnoses of HF in the baseline period. 
The quarter of the initial HF inpatient diagnosis was designated the “index 
quarter”. Each patient was followed for up to two years (8 quarters) after the 
index quarter, or until death or end of enrolment. Frequency of service use based 
on care setting; diagnosis was determined for the “index quarter” and follow-up 
period. RESULTS: A total of 43,819 patients with new primary HF inpatient 
claims were identified in the four year study period. Within the 27 month follow-
up (includes “index”), the identified HF patients had 140,802 inpatient 
hospitalizations (3.2 per patient), of which 66,334 (1.5 per patient) had a primary 
HF diagnosis (includes index HF hospitalization). 23% of identified HF patients 
had one or more HF hospitalizations within two years after the “index”. 
Annualized mortality was 26.4%/year over the first five quarters (includes 
“index”) and 14%/year over quarters 5 through 8. Total mortality was 42.4% 
(18,562/43,819). CONCLUSIONS: Extrapolation of these results suggest that new 
inpatient HF admissions may account for 145,000 HF inpatient hospitalizations. 
HF Mortality after the “index” admission was >40%. Our results underline HF as a 
major clinical and economic burden in the United States.  
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OBJECTIVES: To identify the long term effects of common symptoms of 
pregnancy and whether these increase the risk of cardiovascular disease or 
symptoms associated with it in women at 21 years after pregnancy. METHODS: 
Data used were from the Mater University Study of Pregnancy (MUSP), a 
community- based prospective birth cohort study begun in Brisbane, Australia, 
in 1983. Chi square test and logistic regression analyses were conducted. 
RESULTS: Data were available for 3692 women. In cross tabulations, morning 
sickness, heartburn and backache show positive association (p<0.05) with 
different cardiovascular outcomes. However, in the multivariate models, only 
those experiencing heartburn (adjusted OR 1.3, 95% CI 1.0-1.7) during pregnancy 
were at greater risk of having hypertension 21 years post partum. Women 
experiencing morning sickness (adjusted OR 1.2, 95% CI 0.8-2.0) and backache 
(adjusted OR 1.1, 95% CI 0.6-1.7) were not considered to be at risk for future heart 
disease. CONCLUSIONS: As a whole, our study suggests that most common 
symptoms of pregnancy are not associated with an increased risk of 
cardiovascular disease or with hypertension in the long term.  
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OBJECTIVES: Dronedarone and warfarin are commonly used concurrently in the 
treatment and prevention of stroke caused by atrial fibrillation. Previous data 
from clinical trials suggest a drug-drug interaction between warfarin and 
dronedarone should exist. However, the dosing strategy of warfarin related to 
dronedarone remained unclear in real-world settings. This observational study 
aimed to assess the effect of starting dronedarone in patients with stable INRs in 
daily practice. METHODS: A case-control design was employed. Patients with 
prior stable INRs who started dronedarone between July 2009 and May 2011 were 
identified. After dronedarone was added, subjects with unstable INRs were cases 
and those remaining stable INRs were controls. Data were retrospectively 
collected via charts review. Primary outcomes were pharmacist-judged unstable 
INR status and required warfarin dose adjustments to reach stable INRs again. 
Secondary outcomes were post-INRs and safety measures. Pre-post changes 
were assessed using paired t-tests. Exploratory logistic and linear regression 
models were used to identify predictors for primary outcomes. RESULTS: Of 131 
subjects, 44 (33.6%) were cases. A difference in baseline characteristics between 
groups was a target INR range not 2.0-3.0 (p=0.030), which remains a predictor of 
unstable INRs after adjustments for confounders (OR=7.95, 95% CI 1.58-40.09, 
p=0.012). Forty subjects (30.5%) had increased INRs >0.5, and two (1.5%) had ER 
visits. No dose adjustment was made in controls. Compared to pre-doses, post-
doses were significantly reduced in cases (-5.14 mg or -14.3%, p<0.001). Absolute 
dose changes were associated with pre-dose (p<0.001), INR target not 2.0-3.0 
(p=0.028) and degree of post-INRs deviated from the target (p<0.001). When the 
outcomes were dose changes in percentage, only the latter remained a predictor 
(p<0.001). CONCLUSIONS: After dronedarone was added, warfarin doses were 
downward adjusted in about one-third of patients. The potential drug-drug 
interaction between dronedarone and warfarin should be considered in clinical 
practice.  
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OBJECTIVES: Increasing prevalence of heart failure (HF), increasing enrollment in 
state programs, and the economic burden of hospitalization among Medicaid 
patients necessitate an assessment of the budget impact of key risk factors for 
HF patients in a contemporary Medicaid population. METHODS: Claims from 
Maryland Medicaid, for 14,149 non-dual enrolled, 18-64 year olds with an HF 
diagnosis between July 1, 2005- December 31, 2009, follow-up >=six months. 
Weighted Cox Regression estimated average risk of any hospitalization 
attributable to various comorbidities and first-line therapy use, controlling for 
confounders. Noting the prevalence of comorbidity and therapy use, and mean 
cost of primary HF hospitalization for non-dual enrolled Maryland Medicaid 
patients in 2010 ($16,963 in 2011 dollars), numbers-needed-to-treat (NNT) were 
used to conservatively estimate the expected annual impact to the Maryland 
Medicaid budget attributable to 20% increases in prescribing rates (comorbidity 
prevalence) and associated reduction (increase) in hospitalization rates. 
RESULTS: Most patients were >45 years (71%), female (56%), and black (60%).  
Use prevalence was: beta-blockers (26%), ACE-inhibitors/ARB (29%), aldosterone 
antagonists (AA, 5%), and others including nitrates+hydralazine (37%). 
Comorbidity prevalence: hypertension (73%), psychological disorder (55%), 
chronic ischemic heart disease (CIHD, 43%), diabetes (41%), hyperlipidemia (37%), 
